Related Experiment Video
Updated: Dec 24, 2025
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
1.1K
Botulinum toxin type A in chronic non-dyshidrotic palmar eczema: A side-by-side comparative study
Aisha Ismail1, Samar El-Kholy1, Carmen Farid1
1Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
The Journal of Dermatology
|April 16, 2020
Summary
Intradermal botulinum toxin type A (BTX-A) offers superior, longer-lasting relief for chronic dry palmar eczema compared to standard treatments. This study shows BTX-A significantly improves symptoms and patient satisfaction with minimal side effects.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Intradermal botulinum toxin type A (BTX-A) shows anti-inflammatory and antipruritic properties.
- Limited research exists on BTX-A for dry palmar eczema without hyperhidrosis.
Purpose of the Study:
- To assess the additive efficacy and tolerability of BTX-A in chronic dry palmar eczema.
- To compare BTX-A combined with standard therapy versus standard therapy alone.
Main Methods:
- Prospective, non-randomized, side-by-side comparative study.
- 30 patients with chronic bilateral dry palmar eczema.
- 100 units of intradermal BTX-A added to emollients and topical steroids on one palm versus standard therapy on the other, assessed over 6 months.
Main Results:
- Both treatments were effective and well-tolerated.
- BTX-A combination showed significantly greater symptom reduction and higher patient satisfaction.
- BTX-A efficacy lasted longer (4 months) compared to standard therapy (1 month).
Conclusions:
- Intradermal BTX-A (100 units/palm) is beneficial and well-tolerated for chronic dry palmar eczema.
- Adding BTX-A to topical steroids and emollients provides superior, longer-lasting results.
- BTX-A offers a steroid-sparing effect in managing dry palmar eczema.
